PMHNP Scope of Practice for Weight Loss/GLP-1 in Pennsylvania

If you’re a psychiatrist (or psychiatric NP) looking at the booming telehealth weight-loss market and wondering ‘Can I legally do this?’ — you’re asking the right question. The short answer: Yes, psychiatrists can prescribe weight-loss medications including GLP-1s, but the devil’s in the regulatory details. Between evolving DEA rules, state-by-state telehealth laws, and scope-of-practice gray zones, it’s a compliance minefield if you don’t know the landscape.

Let me walk you through what actually matters — the federal rules that are changing in 2026, which states let you prescribe remotely (and which don’t), and whether adding weight management to your practice is a smart move or a liability risk.

The Federal Picture: DEA’s Telehealth Rules Are in Flux (But Extended Through 2026)

Here’s what keeps most providers up at night: Can I prescribe controlled substances via telehealth without seeing the patient in person?

Pre-COVID, the answer was almost always ‘no’ under the Ryan Haight Act — you needed at least one face-to-face evaluation before prescribing any Schedule II–V controlled drug remotely. During the pandemic, that requirement was waived. As of January 2026, the DEA and HHS extended those flexibilities through December 31, 2026, meaning you can still prescribe controlled medications (including appetite suppressants like phentermine) via telehealth to new patients you’ve never met in person.

But don’t get comfortable. The DEA is actively drafting permanent rules that will likely require either:

• A ‘special telemedicine registration’ for providers who want to prescribe controlled substances remotely, or
• Initial 30-day supply limits for certain controlled drugs prescribed via telehealth, or
• In-person exam requirements for Schedule II substances (stimulants, etc.)

The clock is ticking. If you’re building a telehealth weight-loss practice around controlled substances like phentermine, plan for tighter federal restrictions starting in 2027.

Good news for GLP-1 prescribers: Semaglutide (Wegovy/Ozempic), tirzepatide (Mounjaro/Zepbound), and other GLP-1 agonists are not controlled substances. They’re freely prescribeable via telehealth under federal law — no DEA restrictions, no special registration. The compliance complexity with GLP-1s comes entirely from state medical board rules and standard-of-care requirements, not federal drug scheduling.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Rules: The Real Compliance Bottleneck

Here’s where it gets messy. Even with the federal extension, states can impose stricter telehealth prescribing rules — and several have.

New York: In-Person Exam Required for Controlled Substances (Even Now)

New York didn’t wait for the federal waiver to end. As of May 2025, NY requires at least one in-person medical evaluation before prescribing any controlled substance to a new patient. The only exceptions:

• Another NY provider examined the patient in-person within the past 12 months and shared records
• You’re covering for a colleague who saw the patient face-to-face
• It’s an emergency with an existing patient (5-day supply max)

What this means: If you’re a NY-licensed psychiatrist doing telehealth weight loss and want to prescribe phentermine (Schedule IV), you legally can’t do it via video alone with a brand-new patient. You either need to see them in person first, or coordinate with a local provider who has.

For GLP-1s (non-controlled), you’re fine to prescribe via telehealth in NY with no in-person requirement — just document a thorough video evaluation.

NY’s I-STOP law also mandates checking the state’s Prescription Monitoring Program (PMP) within 24 hours before prescribing any Schedule II, III, or IV drug — and you must e-prescribe everything (paper Rx are nearly extinct in NY except for rare exceptions).

Florida: Telehealth-Friendly, But With Obesity-Specific Mandates

Florida is more permissive. The state allows telehealth prescribing of Schedule III–V controlled substances (including phentermine for weight loss) without an in-person exam. Florida only bans teleprescribing Schedule II drugs via telehealth — except for psychiatric treatment, inpatient/hospice care, or nursing home patients.

Translation: A Florida psychiatrist can prescribe Adderall via telehealth for ADHD (psychiatric carve-out), but not for weight loss. For weight loss, you’d use phentermine (Schedule IV) or GLP-1s, both of which are fine via telehealth in FL.

Florida’s catch: The state has strict obesity prescribing rules (Fla. Admin. Code 64B8-9.012):

• Patients must have BMI ≥30 (or ≥27 with comorbidities) or documented body fat >25% (male)/>30% (female)
• You must obtain written informed consent outlining risks of weight-loss medications
• You must re-evaluate patients every 3 months (can be via telehealth, but must be documented)
• You must provide each patient with Florida’s ‘Weight-Loss Consumer Bill of Rights’ (yes, really)

These aren’t suggestions — they’re enforceable board rules. Florida’s Board of Medicine has disciplined weight-loss clinics in the past for sloppy documentation and misleading advertising. If you’re treating obesity in FL, treat it like you’re building a liability-proof chart every single time.

Also: Florida requires checking the E-FORCSE PDMP before prescribing any controlled substance to patients age 16+. No exceptions.

California: Telehealth Parity, But Watch CPOM and PDMP Rules

California is telehealth-friendly. The state allows telehealth exams to satisfy the ‘appropriate prior examination’ requirement for prescribing — no in-person visit mandated. You can prescribe controlled substances (including phentermine) via video to new patients under the current federal extension.

California-specific compliance points:

• Telehealth consent required: You must obtain and document patient consent for telehealth services (Cal. B&P §2290.5) at the first encounter
• CURES PDMP checks: Before prescribing any Schedule II–IV drug for the first time, and then every 4 months for ongoing therapy, you must query California’s CURES database and document it
• Corporate Practice of Medicine (CPOM): Only physician-owned entities or professional corporations can provide medical services in CA. If you’re a psychiatrist employed by a non-physician-owned telehealth company, that company cannot control your clinical decisions — it’s a legal gray zone that CA regulators scrutinize
• NP supervision: Nurse practitioners operate under ‘Standardized Procedures’ with physician oversight unless they qualify for independent practice under AB 890 (phased in 2023–2026). Even with independence, a psych NP prescribing for obesity may face scope-of-practice questions unless they have additional training

The big news for CA: Medi-Cal (California’s Medicaid) will stop covering GLP-1 medications for weight loss as of January 2026, classifying weight loss as a non-covered benefit. This will push more patients toward cash-pay telehealth models — opportunity if you’re set up for self-pay, challenge if you rely on Medi-Cal reimbursement.

Texas: Permissive on Telehealth, But NP/PA Delegation Is Strict

Texas allows telehealth prescribing of controlled substances (under the federal extension) with no state-imposed in-person requirement for weight-loss drugs. You can prescribe phentermine or GLP-1s via live video to new patients.

Texas rules to know:

• Valid patient relationship: Must establish via live video or equivalent (store-and-forward + audio). Online questionnaire alone doesn’t cut it
• PDMP: Texas requires checking the Tx PMP (AWARxE) before prescribing opioids, benzos, barbiturates, or carisoprodol. Phentermine isn’t on the mandatory list, but best practice (and most clinics’ policies) is to check for any controlled substance
• NP/PA delegation: Texas NPs and PAs must have a Prescriptive Authority Agreement with a supervising physician to prescribe anything, including weight-loss meds. The agreement must explicitly cover obesity treatment if they’re doing it. NPs/PAs cannot prescribe Schedule II drugs outside hospital/hospice settings — but they can prescribe Schedule III–V (phentermine) if delegated
• Follow-up coordination: Texas law requires telehealth providers to send a report to the patient’s primary care provider within 72 hours (with patient consent) to coordinate care

Texas’s high obesity rates (among the highest in the U.S.) create strong demand for weight management. Telehealth is a logical fit for this geographically large state — just make sure your collaborative practice agreements are airtight if you’re working with NPs or PAs.

Pennsylvania: Flexible but Document-Heavy

Pennsylvania has no formal telehealth statute (attempted legislation was vetoed in 2020), but telehealth is permitted under professional standards. The state defers to federal law for controlled substance prescribing, so under the DEA extension, you can prescribe remotely.

PA-specific requirements:

• PDMP checks: Must query the PA PDMP before the first prescription of an opioid or benzodiazepine to a patient, and every time you refill opioids or benzos. For other controlled substances (stimulants, phentermine), the law recommends checking at least once initially
• NP/PA supervision: Pennsylvania CRNPs (nurse practitioners) require a Collaborative Agreement with a physician to prescribe. There’s no independent practice for NPs in PA as of 2025. If a psych NP wants to do weight loss, they’d need a collaborating physician (ideally an internist or bariatric specialist) and the agreement must explicitly delegate weight-loss prescribing authority
• Standard of care: The PA Medical Board expects telehealth prescribing to meet the same documentation and clinical standards as in-person. Thorough history, justification for medication choice, monitoring plan — all required

Pennsylvania’s rural population presents an opportunity for telehealth weight management (limited local access to specialists), but you’ll need to coordinate with primary care providers to build trust and continuity.

Illinois: Telehealth-Friendly, NP Full Practice Authority Available

Illinois is one of the more progressive states for telehealth. The Illinois Telehealth Act (as amended in 2021) allows provider-patient relationships to be established via telehealth, including for prescribing. No in-person exam required if the telehealth encounter meets standard of care.

Illinois highlights:

• Audio-only allowed: Illinois permits audio-only telehealth in some cases (especially mental health), though video is recommended for initial weight-loss evaluations
• NP Full Practice Authority (FPA): Illinois APRNs who complete 4,000 hours of clinical experience and additional training can obtain Full Practice Authority, allowing them to prescribe independently, including Schedule II–V controlled substances (with a consultation agreement for Schedule II opioids). A psych NP with FPA could run an independent weight-loss practice, but scope-of-practice caution applies
• PDMP: Illinois requires checking the PMPnow database each time a Schedule II narcotic (opioid) is prescribed. For other controlled substances (stimulants, phentermine), it’s recommended but not legally mandated — though most providers check anyway for liability protection
• E-prescribing mandate: All controlled substance prescriptions must be sent electronically as of January 2023

Market opportunity: Illinois Medicaid started covering prescription weight-loss medications like Wegovy in 2024 for qualifying patients, which may increase demand. Chicago and suburbs have high competition, but downstate Illinois (more rural) is underserved for specialized weight management.

Psychiatrist vs. PMHNP: Scope of Practice for Weight Loss

Psychiatrists (MD/DO): You have broad prescribing authority. Legally, there’s nothing stopping you from prescribing GLP-1s or phentermine for weight loss — you hold an unrestricted medical license. The question is competence and standard of care. State medical boards expect you to practice within your expertise. If you’re treating obesity:

• Document a thorough evaluation: BMI, comorbidities, diet/exercise history, contraindications
• Obtain informed consent (required in Florida, good practice everywhere)
• Schedule regular follow-ups (every 3 months minimum in FL, monthly early in treatment per obesity medicine guidelines)
• Consider interaction with psychiatric medications (e.g., does phentermine worsen anxiety in your bipolar patient on stimulants?)
• Refer or consult with endocrinology/bariatrics if the case gets complex (e.g., patient needs insulin adjustment on a GLP-1)

Some psychiatrists pursue board certification in Obesity Medicine (offered by the American Board of Obesity Medicine) to bolster credibility and reduce perceived risk of practicing ‘out of scope.’

PMHNPs (Psychiatric Nurse Practitioners): This is trickier. Your licensure and certification are in mental health, not metabolic medicine. Prescribing solely for obesity may be viewed by state nursing boards as outside your scope of practice unless:

• You’re working under a physician’s supervision/collaboration and the physician has expertise in weight management (e.g., an internist or bariatric specialist)
• You obtain additional certification (e.g., AACN’s Adult-Gerontology Acute Care NP or Adult-Gerontology Primary Care NP credential, or obesity medicine training)
• You practice in a state with NP independent practice (like California post-AB 890 or Illinois with FPA) and you can justify competence in obesity treatment (additional coursework, clinical experience)

In states like Texas and Florida, a PMHNP would almost certainly need a supervising physician with obesity treatment experience to prescribe weight-loss drugs legally and safely. Even in independent-practice states, nursing boards expect NPs to practice within their training — a psych NP treating obesity without additional credentials is a liability risk.

The smart play: If you’re a PMHNP interested in weight management, either:

1. Partner with a physician (internist, family med, bariatric specialist) in a formal collaborative agreement that explicitly covers obesity treatment, or
2. Pursue dual certification (become a Family NP or complete obesity medicine training) to expand your scope legitimately, or
3. Focus on psychiatric patients with weight concerns secondary to mental health treatment (e.g., managing metabolic side effects of antipsychotics with metformin or a GLP-1 as part of psychiatric care, not as standalone weight loss) — this stays clearly within your scope

The Economics: Why Telehealth Platforms Beat DIY Marketing (Usually)

Let’s talk about the business case, because compliance doesn’t matter if the economics don’t work.

The DIY marketing illusion: You’ll see articles claiming you can acquire patients for ‘$30–50 per lead’ with smart SEO or Google Ads. That’s fantasy. Here’s the reality of acquiring a qualified psychiatric or weight-loss patient through DIY marketing:

• SEO: Takes 6–12 months of consistent investment (content, backlinks, technical optimization) before generating meaningful patient flow. You’re paying an agency $2,000–5,000/month during that ramp-up period with zero guaranteed return
• Google Ads: Mental health and weight-loss keywords cost $15–40+ per click (highly competitive). Most clicks don’t convert to booked appointments. Factor in testing campaigns, optimizing ad copy, hiring someone to manage it, handling and qualifying leads, no-shows from cold traffic — realistic cost per booked patient through PPC is $200–400+, not $30
• Directory listings: Psychology Today charges monthly fees ($30–60) but you’re competing with hundreds of other providers on the same page. Zocdoc charges per booking ($35–100+ depending on specialty and market) plus a monthly subscription. Total monthly cost easily exceeds $500–1,000 for uncertain results
• Hidden costs: Staff time to answer phones, qualify leads, follow up with no-shows. Failed marketing campaigns that burn budget. Opportunity cost of your time learning marketing instead of seeing patients

Realistic all-in CAC (customer acquisition cost) for solo providers doing their own marketing: $200–500+ per patient when you account for all costs, and that’s after months of investment with no guaranteed volume.

The platform model (like Klarity): Instead of gambling $3,000–5,000/month on marketing with uncertain ROI, you pay a standard listing fee per new patient lead (similar to Zocdoc’s per-booking model). Key differences:

• No upfront spend: You don’t pay anything until a qualified patient books with you
• Pre-qualified patients: Leads are already matched to your specialty, availability, and insurance (if applicable) — no wasted ad clicks on people looking for therapists when you’re a prescriber, or vice versa
• Guaranteed ROI: You know exactly what each patient costs before you see them. If a patient doesn’t show or isn’t a fit, you’re not out thousands in sunk ad spend
• Built-in infrastructure: Integrated telehealth platform (no separate Zoom subscription), EHR, credentialing support, billing support for insurance patients — costs that would otherwise run $200–500/month separately
• Both insurance and cash-pay flow: Platforms typically offer both, letting you balance volume (insurance) with margin (cash-pay)
• You control your schedule: Only pay when you see patients. If you need to scale down (vacation, personal leave), you’re not locked into monthly marketing contracts

When DIY makes sense: If you have the budget ($5,000–10,000/month), patience (6–12 months to see ROI), and expertise (or are willing to hire a healthcare marketing agency), building your own patient acquisition engine can eventually be cost-effective. But for most providers — especially those starting out, scaling a new service line, or testing a market — a platform that handles patient acquisition removes the risk entirely.

The bottom line: A platform’s per-patient fee might look higher than a $30 Google click, but when you compare total cost per booked patient and time to first patient, platforms almost always win for solo/small practices.

Risk Management: What Gets Providers in Trouble

State medical boards and DEA investigators look for patterns. Here’s what triggers complaints or audits in telehealth weight-loss practices:

1. No documented exam: ‘Patient filled out online form, got prescription’ — that’s not a valid patient-provider relationship in any state. You need synchronous interaction (video, at minimum phone in some states) and thorough documentation

2. Skipping PDMP checks: If your state mandates it (most do for controlled substances), failing to query the database before prescribing phentermine or other controlled drugs is a fast track to discipline

3. No follow-up: Prescribing 90-day supplies of phentermine with no scheduled re-evaluation violates standard of care in most states (Florida explicitly requires every 3 months for obesity meds)

4. Scope creep without credentials: A psych NP prescribing for obesity with no physician oversight, no additional training, and no documentation of competence — nursing boards will view this as practicing outside scope

5. Misleading advertising: Guaranteeing weight loss, using fake before/after photos, implying FDA approval for off-label compounded drugs — these violate state consumer protection laws and medical board advertising rules

6. Poor coordination: Not informing the patient’s primary care provider when starting a GLP-1 (especially if the patient has diabetes or is on other meds that interact) — this violates standard of care and opens liability risk if something goes wrong

Defensive documentation is your friend:

• Initial evaluation note: detailed history, weight/BMI, prior weight loss attempts, comorbidities, contraindications assessed, informed consent obtained
• Treatment plan: specific medication, dosing rationale, titration schedule, diet/exercise counseling provided (or referral given), follow-up interval
• PDMP query documentation: date checked, any concerning findings, clinical decision based on results
• Follow-up notes: weight change, side effects assessed, medication effectiveness, labs reviewed (if applicable), plan for continuation/adjustment/discontinuation

FAQ: What Providers Actually Want to Know

Can I prescribe semaglutide (Ozempic/Wegovy) via telehealth to new patients I’ve never met in person?
Yes, in most states — semaglutide is not a controlled substance, so DEA’s in-person exam rules don’t apply. You need to establish a valid telehealth patient relationship (typically live video) that meets your state’s standard of care. Document a thorough evaluation (BMI, comorbidities, contraindications, informed consent), create a treatment plan, and schedule follow-ups. Check your state’s specific telehealth requirements (e.g., California requires telehealth consent documentation; Florida requires written informed consent for obesity meds and quarterly re-evaluations).

Do I need an in-person visit to prescribe phentermine online?
It depends on your state:

• New York: Yes, you need at least one in-person medical evaluation (or documented exam by another NY provider within the past 12 months) before prescribing any controlled substance
• Florida, Texas, California, Pennsylvania, Illinois: No state-level in-person requirement currently (you can prescribe phentermine via telehealth under the federal DEA extension through December 31, 2026). But you must use live video (or equivalent telehealth modality per state law), check your state’s PDMP, and document a thorough evaluation
• All states: Once the DEA’s final permanent telehealth rules are published (likely late 2026 or 2027), federal in-person requirements may return for controlled substances. Stay current on DEA announcements.

As a PMHNP, can I legally offer weight-loss treatment?
Usually requires physician collaboration or additional certification, since treating obesity is generally outside a psychiatric NP’s scope of practice. Your options:

• With supervision: Work under a collaborative agreement with a physician who has expertise in obesity/metabolic medicine (e.g., internist, endocrinologist). The agreement should explicitly delegate weight-loss prescribing. This works in all states but requires finding the right collaborating physician
• With independent practice + training: In states that allow NP independent practice (California with AB 890, Illinois with FPA), you could practice independently if you have additional credentials in obesity medicine or primary care and can document competence. Even so, nursing boards scrutinize NPs practicing outside their certification area
• Staying within psych scope: Focus on weight management as part of psychiatric care — e.g., managing metabolic side effects of antipsychotics with metformin or a GLP-1, or treating binge eating disorder with medication and therapy. This keeps you clearly within psychiatric practice and reduces regulatory risk

Bottom line: Don’t try to operate a standalone weight-loss clinic as a PMHNP without physician collaboration or verifiable additional training — the liability and regulatory risk aren’t worth it.

What happens when the DEA’s telehealth extension expires in 2026?
The DEA plans to finalize permanent rules before or shortly after December 31, 2026. Likely outcomes based on their 2025 proposals:

• Special telemedicine registration: Providers who want to prescribe Schedule III–V controlled substances via telehealth may need to obtain a special DEA registration (in addition to their regular DEA number). This would allow remote prescribing to patients you’ve never seen in person, but with some limits (possibly 30-day initial prescriptions, annual registration renewal)
• Schedule II restrictions: For Schedule II drugs (like Adderall), the DEA may require either an in-person exam or limit telemedicine prescribing to certain specialties (e.g., allowing psychiatrists to prescribe stimulants via telehealth for ADHD, but not allowing it for weight loss or other indications). They’re seeking public comment on this
• State licensure: Prescribers will need to be fully licensed in the state where the patient is located (no federal telemedicine license exists)

What you should do now: Monitor DEA announcements (sign up for DEA Diversion Control updates). If you’re building a practice around telehealth controlled-substance prescribing (e.g., phentermine for weight loss), have a contingency plan for 2027 — either pivot to non-controlled medications (GLP-1s), establish in-person exam pathways (partner with local clinics for initial visits), or prepare to obtain the new special registration if it becomes available.

Can I prescribe to patients in other states via telehealth?
Only if you’re licensed in the state where the patient is physically located at the time of the telehealth encounter. There is no federal telehealth license. Options to practice in multiple states:

• Interstate Medical Licensure Compact (IMLC): If you’re in a Compact state, you can use the IMLC to expedite licenses in other Compact states (currently 40 states participate as of 2025, including recent additions like New York). This is faster and cheaper than applying for each state license individually, but you still need to get a license in each state where you want patients
• Nurse Licensure Compact (NLC): For NPs, the NLC allows you to practice in other Compact states with your home state license (30+ states participate). However, prescribing authority is governed by the state where the patient is located, so you may still need to meet that state’s NP collaboration/supervision requirements
• State-by-state licensure: If you’re not in a Compact or want to practice in non-Compact states (e.g., California), you’ll need to apply for individual state licenses. This is time-consuming and expensive ($500–2,000 per state license, plus ongoing renewal fees), but necessary if you want to build a truly national telehealth practice

Controlled substances add another layer: Even if you’re licensed in multiple states, you need a DEA registration in each state where you’ll be prescribing controlled substances. Under current rules, you can use your primary DEA number + state registration, but check with the DEA and each state’s requirements.

The Verdict: Should You Add Weight Loss to Your Telehealth Practice?

If you’re a psychiatrist:
Adding GLP-1-based weight management to your practice is low regulatory risk (they’re not controlled substances, so no DEA complications beyond normal prescribing) and high demand (especially for patients already seeing you for mental health who also struggle with weight/metabolic issues from meds). The business case is strong — GLP-1s are cash-pay friendly (many insurers don’t cover for weight loss), margins are decent, and it’s a natural service extension for psychiatric patients.

Controlled substances (phentermine, etc.) add complexity — you need to navigate state PDMP requirements, potential in-person exam rules (New York), and the looming DEA rule changes in 2026–2027. If you’re going to prescribe controlled weight-loss meds, treat it like you would any controlled substance practice: rigorous documentation, regular monitoring, PDMP checks, and be prepared for tighter federal oversight soon.

If you’re a PMHNP:
Proceed with caution. Weight loss treatment is outside your usual scope unless you have a solid collaborative agreement with a physician (internist, family med, or bariatric specialist) or additional certification in primary care/obesity medicine. States are watching NPs for scope creep — don’t give regulators a reason to flag your practice.

The safer path: Focus on weight management within psychiatric care (managing med side effects, treating binge eating disorder) where your expertise is clear, or partner with a physician who can supervise the obesity treatment component while you handle the mental health side.

For everyone:
Use a platform like Klarity Health if you want to test the weight-loss market without burning $5,000+/month on marketing. You pay only when you see patients, get pre-qualified leads matched to your availability, and leverage built-in telehealth infrastructure. It’s guaranteed ROI vs. gambling on DIY marketing channels that may or may not work.

Stay on top of regulatory changes — the DEA’s 2026 deadline is real, and state medical boards are increasingly scrutinizing telehealth obesity prescribing for quality and safety. Document everything, follow PDMP mandates, get proper consent, schedule regular follow-ups, and coordinate with primary care.

Done right, telehealth weight management is a legitimate, profitable addition to a psychiatric practice. Done wrong (cutting corners on exams, skipping PDMP checks, practicing outside your scope), it’s a fast track to board complaints and DEA audits.

Sources and References

1. U.S. Department of Health & Human Services – Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (Jan 2, 2026) – Official DEA/HHS policy statement confirming extension of COVID-era telehealth prescribing rules through December 31, 2026. www.hhs.gov

2. Medical Director Compliance Consulting – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (2025) – Comprehensive state-specific guide covering Texas delegation requirements, PDMP rules, and DEA registration for weight-loss prescribing. Cites Texas Occupations Code and administrative rules. www.medicaldirectorco.com

3. Florida Statutes § 456.47 – Use of Telehealth to Provide Services (Florida Telehealth Act) (2019, accessed Nov 2025) – Official state statute governing telehealth practice standards in Florida, including controlled substance prescribing restrictions. florida.public.law

4. Goodwin Law – Client Alert: ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (Mar 30, 2024) – Detailed legal analysis of state-specific obesity prescribing rules in Florida, New Jersey, and Virginia. Written by healthcare attorneys. www.goodwinlaw.com

5. Fierce Healthcare – ‘Primary care doctors concerned about telehealth GLP-1 boom: survey’ by Heather Landi (Feb 13, 2025) – Reports physician survey results on concerns about telehealth weight-loss prescribing quality and patient safety. www.fiercehealthcare.com

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated